Characterization of cis-acting sequences involved in packaging porcine adenovirus type 3

Li Xing and Suresh Kumar Tikoo*

Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Saskatchewan, Canada S7N 5E3

Received 26 March 2003; returned to author for revision 30 April 2003; accepted 16 June 2003

Abstract

Encapsidation of adenovirus DNA involves specific interactions between cis-acting genomic DNA sequences and trans-acting proteins. The cis-acting packaging domain located near the left inverted terminal repeat is composed of a series of redundant but not functionally equivalent motifs. Such motifs are made up of the consensus sequence 5′-TTTGN8CG-3′ and 5′-TTTG/A-3′ in human adenovirus 5 (HAV-5) and canine adenovirus-2 (CAV-2), respectively. To gain comparative insight into adenovirus encapsidation, we examined the packaging domain of porcine adenovirus-3 (PAV-3). Using deletion mutants, we localized the PAV-3 packaging domain to 319 bp (nt 212 to 531), which contains six cis-acting elements. However, this domain does not contain the consensus motifs identified in HAV-5. In addition, consensus motif found in CAV-2 is present only once in PAV-3. Instead, PAV-3 packaging domain appears to contain AT/GC-rich sequences. The packaging motifs of PAV-3, which are functionally redundant but not equivalent, are located at the left end of the genome. © 2003 Elsevier Inc. All rights reserved.

Since adenoviruses have become popular as vectors for the delivery of foreign genes in mammalian cells, constant attempts are being made to develop adenovirus vectors with improved capacity, safety, and efficacy (Russell, 2000). To achieve this, detailed knowledge of biology of adenovirus including mechanisms of virus particle assembly and viral DNA packaging is necessary. Although analysis of adenovirus particle assembly has been the focus of many studies (D’Halluin et al., 1978a, 1978b, 1980; Edvardsson et al., 1976, 1978), little is known about the basic mechanism of encapsidation of adenovirus DNA.

Earlier studies using temperature-sensitive mutants and pulse-chase kinetics experiments have established that adenovirus DNA is inserted into preformed, empty capsids late in the viral life cycle (D’Halluin, 1995). Other studies on viral incomplete particles containing DNA molecules of subgenomic length suggested that DNA packaging occurs in a polar fashion from left to right (Daniell, 1976; Tibbetts, 1977; Hammarskjold and Winberg, 1980; Kosturko et al., 1982; Robinson and Tibbetts, 1984). Subsequent studies suggested that a cis-acting packaging domain located in the left end of the adenovirus genome is required for the selective encapsidation of viral DNA (Grable and Hearing, 1990, 1992; Hearing et al., 1987). However, the position and the orientation of this packaging domain is not strict as long as it is within first or last 600 bp (Hasson et al., 1989; Hearing and Shenk, 1983; Hearing et al., 1987).

The cis-acting packaging domain in human adenovirus type 5 (HAV-5) is located in the left end 380 bp (Hearing et al., 1987). It contains at least seven functionally redundant “A-repeat” domains (Grable and Hearing, 1990, 1992), four of which (AI, AII, AV, and AVI) are most dominant (Schmid and Hearing, 1997). Mutational analysis of A-repeat consensus sequence (5′-TTTGN8CG-3′) suggested that sequence as well as the spacing (N8) of two elements 5′-TTTG-3′ and 5′-CG-3′ are critical for maximum packaging capacity (Schmid and Hearing, 1997). In addition to cis-acting sequences, a number of viral and/or cellular proteins are thought to be involved in adenovirus DNA packaging (Fujisawa and Hearing, 1994; Grable and Hearing, 1992; Schmid and Hearing, 1995). Schmid and Hearing have detected some cellular proteins binding to the packaging sequences (Schmid and Hearing, 1997). Among viral pro-

* Corresponding author. 120 Veterinary Road, University of Saskatchewan, Saskatoon, SK, Canada S7N 5E3. Fax: +306-966-7478.
E-mail address: Tikoo@sask.usask.ca (S.K. Tikoo).

1 Published as VIDO Journal article no. 340.
teins, the 52/55-kDa and IVa2 proteins have been shown to date to be required for viral DNA packaging (Gustin and Imperiale, 1998; Hasson et al., 1989; Zhang et al., 2000, 2001). Interaction of IVa2 with the different components of the DNA packaging machinery has been shown to be serotype specific (Zhang et al., 2000, 2001). Although identity of some of these proteins is becoming known, the nature of interactions between different components of the packaging machinery remains unclear.

Recently, cis-acting packaging domain of canine adenovirus-2 (CAV-2) has been identified (Soudais et al., 2001). Similar to HAV-5 (Schmid and Hearing, 1997), cis-acting packaging motifs of CAV-2 are located in the left end of the genome and are functionally redundant (Soudais et al., 2000, 2001). Although identity of some of these proteins is becoming known, the nature of interactions between different components of the packaging machinery remains unclear.

Recently, cis-acting packaging domain of canine adenovirus-2 (CAV-2) has been identified (Soudais et al., 2001). Similar to HAV-5 (Schmid and Hearing, 1997), cis-acting packaging motifs of CAV-2 are located in the left end of the genome and are functionally redundant (Soudais et al., 2000, 2001). Although identity of some of these proteins is becoming known, the nature of interactions between different components of the packaging machinery remains unclear.

Results

Analysis of the PAV-3 genomic sequences

The cis-acting packaging domain of canine adenovirus-2 (Soudais et al., 2001) and most human adenoviruses (Grable and Hearing, 1990, 1992; Hammarskjold and Winberg, 1980; Hearing et al., 1987; Kosturko et al., 1982; Schmid and Hearing, 1997) appears to be located near the left end of the genome between inverted terminal repeat (ITR) and the start of E1A coding region. However, the position and orientation of the packaging domain is not strict as long as it is within the first or the last 600 bp of the genome (Hammarskjold and Winberg, 1980; Hearing and Shenk, 1983; Hearing et al., 1987). The ITR of PAV-3 is 144 bp in length (Reddy et al., 1998a). Based on the consensus sequences of cis-acting packaging motif of human adenovirus 5 [5'-TTTGGNGC-3'] (Schmid and Hearing, 1997), we searched PAV-3 genome for putative cis-acting packaging motifs in two regions of the viral genome (between left ITR and E1A gene and between right ITR and E4 region). We could not find any motif that showed perfect homology with the consensus packaging motifs of HAV-5 between left ITR and E1A gene and between right ITR and E4 region. In addition, availability of cis-acting packaging domain of PAV-3 may help in the construction of hybrid (PAV-3/HAV-5) gutless adenovirus vectors, thus helping to eliminate or substantially reduce the helper virus contamination. In the present study, we identified the packaging domain of porcine adenovirus 3 (PAV-3) by constructing and analyzing packaging deletion mutants.

Fig. 1. Nucleotide sequence of PAV-3 termini. Numbers indicate the nucleotide position relative to the left terminus of PAV-3 genome. Inverted terminal repeat (ITR) nucleotide sequence is shown in italic. (A) Nucleotide sequence of left terminus. The cap site A and ATG codon for E1A gene are shown in italic bold case. AT-rich regions are in bold case. (B) Nucleotide sequence of PAV-3 right terminus. TTTG motif is shown in bold case.
PAV-3 (Fig. 1). To characterize which of them could function in cis as packaging motifs for PAV-3 DNA, deletion mutations were introduced into intact viral genome to delete these candidate motifs in single fashion or in combinations.

Isolation of mutant viruses

To define cis-acting sequences required for packaging PAV-3 DNA, initially, deletion mutations were constructed in a recombinant transfer plasmid pPAV3.Eco47-3 (Fig. 2A) by replacing DNA sequences located between BamHI-EcoRV restriction enzyme sites or between HpaI-PacI restriction enzyme sites with two PCR DNA fragments in a three-way ligation. The individual deletions were then introduced into intact viral genome (Fig. 2B) by homologous recombination between wild-type PAV-3 genomic DNA and Eco47-3-linearized individual recombinant transfer plasmid in Escherichia coli B15183 cells (Chartier et al., 1996). The PacI-digested individual full-length plasmid DNA, transfected into VIDO R1 cells, produced cytopathic effects (CPE) in 14 to 21 days. The infected cell monolayers showing 50% cytopathic effects were collected and freeze-thawed, and recombinant viruses were plaque purified and propagated in VIDO R1 cells.

To confirm the presence of specific deletion(s), we analyzed the genomic DNA by PCR using primers generated from the flanking regions of the deletions (Table 1). Mutant viral DNAs were PCR amplified using primer pairs PSR32-P2 for deletions between left ITR and E1A gene (Fig. 3A, C, D, and E) or PR1-PSR32 for deletions between E4 region and right ITR (Fig. 3B) and observed for a shift in the size of their products generated due to deletions in the mutants, compared to wild-type PAV-3 DNA (Fig. 3). Compared to the wild-type PAV-3, all the deletion mutants yielded the expected amplification products. Finally, the identity of each deletion was confirmed by DNA sequence analysis of the PCR fragments amplified using mutant viral DNA(s).

Analysis of mutant viruses with internal deletions

Most of deletion mutations in this study were located between nucleotide (nt) position 151 and 531, which also contain the regulatory region of PAV-3 E1A transcription unit (Reddy et al., 1998a). The mutation in this region could probably affect the expression of E1A gene and thus result in the changes in viral growth of mutant PAV-3, or even make the virus nonviable. Since VIDO R1 cells could complement the E1A defect of PAV-3 (Reddy et al., 1999b), this cell line was used throughout this study.
Table 1
Primers used in PCR

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequencea</th>
<th>PAV-3 nucleotide positionb</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>5'-CGT CTT CAA GGA TCC TTA-3'</td>
<td>minus 23–minus 5</td>
<td>Sense, BamHII</td>
</tr>
<tr>
<td>P2</td>
<td>5'-CGC GCT GAT ATC CTC CTC-3'</td>
<td>827–844</td>
<td>Antisense, EcoRV</td>
</tr>
<tr>
<td>P3</td>
<td>5'-CCG CAA TTAG GTC ATC ACA CGT CAT TTT C-3'</td>
<td>133–151</td>
<td>Antisense, MfeI</td>
</tr>
<tr>
<td>P4</td>
<td>5'-CCG CAA TTAG GGG GGG GGG CGG AGG GCC-3'</td>
<td>213–230</td>
<td>Sense, MfeI</td>
</tr>
<tr>
<td>P5</td>
<td>5'-CCG CAA TTAG GGC GAG GAC CGC CCC AGG-3'</td>
<td>195–212</td>
<td>Antisense, MfeI</td>
</tr>
<tr>
<td>P6</td>
<td>5'-CCG CAA TTAG ATA CGG CCY GAT TTT GT-3'</td>
<td>255–271</td>
<td>Sense, MfeI</td>
</tr>
<tr>
<td>P7</td>
<td>5'-CCG CAA TTAG CTC CAC CTG TGC GGG AAT-3'</td>
<td>235–252</td>
<td>Antisense, MfeI</td>
</tr>
<tr>
<td>P8</td>
<td>5'-CCG CAA TTAG CAC CAC AGC TCG GGG G-3'</td>
<td>313–328</td>
<td>Sense, MfeI</td>
</tr>
<tr>
<td>P9</td>
<td>5'-CCG CAA TTAG CGG CAG TGC CAC ACC GGA-3'</td>
<td>295–312</td>
<td>Antisense, MfeI</td>
</tr>
<tr>
<td>P10</td>
<td>5'-CCG CAA TTAG TCG CGC TGA GAG GTC GCC GGC G-3'</td>
<td>383–401</td>
<td>Sense, MfeI</td>
</tr>
<tr>
<td>P11</td>
<td>5'-CCG CAA TTAG AGG ACA CCC CGC TCA GTG-3'</td>
<td>365–382</td>
<td>Antisense, MfeI</td>
</tr>
<tr>
<td>P12</td>
<td>5'-CCG CAA TTAG TTT TTT CCC CTC AGT GTA TA-3'</td>
<td>433–452</td>
<td>Sense, MfeI</td>
</tr>
<tr>
<td>P13</td>
<td>5'-CCG CAA TTAG TAC ACC CAC ACA GTG CAT-3'</td>
<td>415–432</td>
<td>Antisense, MfeI</td>
</tr>
<tr>
<td>P14</td>
<td>5'-CCG CAA TTAG TAT ACC CAC ACA GTG CAT-3'</td>
<td>449–463</td>
<td>Sense, MfeI</td>
</tr>
<tr>
<td>P15</td>
<td>5'-CCG CAA TTAG ACT GAG GGG AAA AAA TAC-3'</td>
<td>430–447</td>
<td>Antisense, MfeI</td>
</tr>
<tr>
<td>P16</td>
<td>5'-CCG CAA TTAG GTC ACT ACT CTT GAG TCC-3'</td>
<td>474–491</td>
<td>Sense, MfeI</td>
</tr>
<tr>
<td>P17</td>
<td>5'-CCG CAA TTAG CGC GGA CTA TAT ACA CTG-3'</td>
<td>444–461</td>
<td>Antisense, MfeI</td>
</tr>
<tr>
<td>P18</td>
<td>5'-CCG CAA TTAG GGA TAG AGT TTG CTT CTC TCA-3'</td>
<td>497–514</td>
<td>Sense, MfeI</td>
</tr>
<tr>
<td>P19</td>
<td>5'-CCG CAA TTAG CTT CGC ACT CGA GAG TAG-3'</td>
<td>478–495</td>
<td>Antisense, MfeI</td>
</tr>
<tr>
<td>P20</td>
<td>5'-CCG CAA TTAG ACA TGG CGA ACA GAC TCT-3'</td>
<td>531–548</td>
<td>Sense, MfeI</td>
</tr>
<tr>
<td>PR1</td>
<td>5'-CCG CCT CGG CCG TTA CCA CGA TTC ACC-3'</td>
<td>33838–33861</td>
<td>Sense, HpaI</td>
</tr>
<tr>
<td>PR2</td>
<td>5'-AGG TTT TAA TAA ACA TCA TC-3'</td>
<td>34088–34094</td>
<td>Antisense, PacI</td>
</tr>
<tr>
<td>PR3</td>
<td>5'-CCG CAA TTAG CGC AGG TCG CGC CGG AGC-3'</td>
<td>33894–33911</td>
<td>Antisense, MfeI</td>
</tr>
<tr>
<td>PR4</td>
<td>5'-CCG CAA TTAG CCT CGG ACT TTT ACC GT-3'</td>
<td>33926–33942</td>
<td>Sense, MfeI</td>
</tr>
<tr>
<td>PR5</td>
<td>5'-CCG CAA TTAG GGC GGG GTC AAA GTC GCA-3'</td>
<td>33908–33926</td>
<td>Antisense, MfeI</td>
</tr>
<tr>
<td>PR6</td>
<td>5'-CCG CAA TTAG CCA CGT CAT TTT CCC A-3'</td>
<td>33949–33965</td>
<td>Sense, MfeI</td>
</tr>
<tr>
<td>PSR32</td>
<td>5'-CCG CGG GAT CTT TAA TTA ACA TCA TCA ATA ATA TAT CGC AGC AAT TT-3'</td>
<td>1–18</td>
<td></td>
</tr>
</tbody>
</table>

aThe restriction endonuclease cleavage sites are underlined.
bNumbers indicate the nucleotide position relative to the left terminus of PAV-3 (Reddy et al., 1998b) genome. PAV-3 nucleotide sequences are indicated in boldface type.

To analyze the efficiency of packaging of the mutant viral DNA, we used two assays. First, we determined the yield of infectious virus in single infection on VIDO R1 cells by plaque assay. Since deletion of part of E1A region of PAV-3 genome has been shown to lead to reduced virus yield in VIDO R1 cells (Reddy et al., 1999b), we also used a coinfection assay. In this assay, VIDO R1 cells were coinfected with wild-type and mutant PAV-3 at the same m.o.i. At 2 days after infection, one-half of the cells were used to isolate the high-molecular-weight nuclear DNA and the other half of the cells were used to isolate the viral DNA from virion particles (Grable and Hearing, 1990, 1992). The coinfected viral genomes could be distinguished by digestion of viral DNA with MfeI and KpnI and by subsequent Southern hybridization analysis.

In the first set of mutant viruses, the small deletions were targeted at the left (Fig. 4A; nt 151 to 531) and right (Fig. 4A; nt 33911 to 33949) end of PAV-3 genome. As seen in Fig. 4, the results of the single infection in VIDO R1 cells showed that deletions extending from nt 151 to 213, 212 to 254, 252 to 313, 312 to 383, 432 to 449, and 461 to 497 resulted in two- to sevenfold reduction in the yield of PAV-3. However, in coinfection assays (Fig. 4B), deletions extending from nt 151 to 213 and 461 to 497 had no effect on the packaging abilities of mutant viruses (Fig. 4A). In addition, deletions extending from 382 to 433 had no effects on the yield of PAV-3 in single infection as well as packaging ability of the virus in coinfection assays (Fig. 4A). These results suggested that these regions do not contain packaging motif(s). In contrast, the changes in packaging efficiency in coinfection assays (Fig. 4B) were evident with mutant viruses containing deletions between nt 212 and 254 (Pav3-212/254), nt 252 and 313 (Pav3-252/313), nt 312 and 383 (Pav3-312/383), nt 432 and 449 (Pav3-432/449), nt 447 and 474 (Pav3-447/474), and nt 495 and 531 (Pav3-495/531). However, the mutant viruses containing deletions between nt 33911 to 33949 at the right end of viral genome grew as well as wild-type virus in VIDO R1 cells in single infection (Fig. 4A). These results suggested that the packaging domains of PAV-3 are (a) located at the left end of viral genome, (b) possibly functionally redundant as described for human adenovirus type 5 (Grable and Hearing, 1990; 1992; Schmid and Hearing, 1997), and (c) appeared to overlap the promoter region of E1A gene.
Analysis of mutant viruses with progressive deletions

To further define the packaging domain of PAV-3, we constructed two additional sets of mutant viruses. One set of mutant viruses contains deletions, which progress from a common site at nt 151 toward the downstream border of the packaging domain (Fig. 5A). As seen in Fig. 5, mutant Pav3-151/254 carrying deletion between nt 151 and 254 had a twofold reduction in virus yield in single infection and a twofold reduction in the packaging ability in coinfection assays. The sequential additional deletions from nt 254 to 313 (Pav3-151/313) and 313 to 383 (Pav3-151/383) resulted in a five-to eightfold reduction in viral yields in single infection, and three-to sevenfold reduction in packaging ability in coinfections, respectively. These results suggested that there are packaging motifs located between nt 254 and 313 and nt 313 and 383. The additional deletions extending from nt 383 to 497 (Pav3-151/433, Pav3-151/449, Pav3-151/474, Pav3-151/497) did not result in the further significant reduction in viral growth in single infection and in packaging ability in coinfection assays. Although deletion from nt 497 to 531 is not lethal, deletion extending from nt 151 to 531 (Pav3-151/531) resulted in the loss of virus viability, suggesting that the sequence between nt 497 to 531 contains a packaging motif which alone can support the packaging of PAV-3. This motif probably represented the downstream border packaging motif. Surprisingly, the mutant with a deletion between nt 151 and 449 (Pav3-151/449) showed 20-fold reduction in the virus yield in VIDO R1 cells in a single infection. The reasons for this phenomenon remain unclear.

A second set of viral mutants was constructed which contained unidirectional deletions progressing from a common site at nt 531 toward the upstream border of the packaging domain (Fig. 6A). As seen in Fig. 6A, we could not isolate a viable mutant PAV-3 when deletions extended from nt 531 to 212 (Pav3-212/531). The results suggested that the packaging domain of PAV-3 existed between nt 212 and 531. The addition of DNA sequences between nt 212 and 252 (Pav3-252/531) made the virus viable, suggesting that there exists a packaging motif in this region, which alone can make the mutant virus viable (Figs. 6A and B).
Fig. 4. Analysis of viral mutants carrying individual deletions. (A) Schematic view of viral mutants. The top of the figure shows the position of AT/GC-rich motifs (filled box); E1A cap site (filled circle) and E1A ATG (arrow head), and structure of the left terminus of PAV-3 genome. The individual deletion mutant names are given on the left. The nucleotide numbers correspond to the first nucleotides present on either side of the deletion. The deleted sequences are indicated by dotted line. Mutant virus yields (YIELD) are expressed as the fold reduction in yield relative to that of wild-type virus. Mutant virus packaging efficiency (COINF) is expressed as the fold reduction in packaged mutant DNA relative to the packaged coinfecting wild-type DNA. The data were normalized to the amount of each viral DNA (mutant and wild-type) present in total DNA. NT, not tested. (B) Southern hybridization analysis of viral DNA represented either in total DNA or in virion particles isolated from VIDO R1 cells coinfected with wild-type and the mutant viruses. Total nuclear DNA and virion DNA were digested with MfeI and KpnI and subsequently subjected to Southern hybridization analysis using PAV-3 left-end and fragment between nt 531 and 844 as a [32P]-labeled probe. The corresponding wild-type (WT) and mutant (MU) left-end DNA fragments are indicated. The mutant viruses tested were Pav3-151/213 (lane 1), Pav3-212/254 (lane 2), Pav3-252/313 (lane 3), Pav3-312/383 (lane 4), Pav3-382/433 (lane 5), Pav3-432/449 (lane 6), Pav3-447/474 (lane 7), Pav3-461/497 (lane 8), Pav3-495/531 (lane 9). (C) Results of the phosphoimager scanning of DNA band intensity are shown.
This motif represented the upstream border of the packaging domain of PAV-3. The sequential addition of DNA sequences between nt 252 and 382 (Pav3-312/531, Pav3-382/531) resulted in a five- to ninefold increase in the yield and a one- to fourfold increase in the packaging ability compared with that of mutant virus Pav3-252/531 (Figs. 6A and B). These results suggested that there appears to be two packaging motifs located between nt 252 and 382. The addition of DNA sequences between nt 382 and 432 (Pav3-432/531) had no effect either on the yield or on the packaging ability of PAV-3. However, the addition of DNA sequences between nt 432 and 447 resulted in onefold increase in the virus yield and twofold increase in the packaging ability when compared with that of Pav3-432/531, suggesting that a packaging motif exists between nt 432 and 447 (Figs. 6A and B). Although there was no difference in the yield of Pav3-447/531 and Pav3-461/531 in single infection, addition of nt 447 to 461 resulted in a onefold increase in the packaging ability of Pav3-461/531. This suggested that nt 447 to 461 may contain a packaging motif.

Although Pav3-151/449, Pav3-151/433, and Pav3-151/474 showed comparable packaging ability in coinfection assays (Fig. 5), Pav3-151/449 showed a two and one-half fold more reduction in virus yield than Pav3-151/433 or Pav3-151/474 in single infection of VIDO R1 cells. To reconfirm these observations, we constructed another set of mutants with deletions progressing from a common site at nt 449 toward the upstream border of packaging domain at nt 212 (Fig. 7A). The sequential addition of DNA sequences between nt 212 and 252 (Pav3-252/449), 252 and 312 (Pav3-312/449), and 312 and 382 (Pav3-382/449) increased the packaging ability of PAV-3 correspondingly in a coinfection assay (Fig. 7A and B). These data are in agreement with that described above (Fig. 5) and confirm that packaging motifs exist in these three regions. In contrast, there was still significant reduction in the yield of Pav3-212/449 and Pav3-252/449 in VIDO R1 cells in a single infection assay (Fig. 7A). However, the addition of DNA sequences between nt 252 and 312 enhanced significantly the viral growth in VIDO R1 cells, although it made the viral packaging ability increase slightly. These data suggested that DNA sequences between nt 252 and 312 may have other unknown functions in viral life cycle which significantly affect the yield of the PAV-3.

Discussion

Adenoviruses appear to package its DNA in preformed empty capsids (D’Haluin et al., 1978a, 1978b, 1980; Edwardsson et al., 1976, 1978) by recognition of specific viral sequences by viral and cellular packaging proteins (Fujisawa and Hearing, 1994; Grable and Hearing, 1992; Schmid and Hearing, 1995, 1998). Although the identity of viral and cellular proteins that interact with packaging domain is becoming clear (Gustin and Imperiale, 1998; Hasson et al., 1989; Schmid and Hearing, 1998; Zhang et al., 2000, 2001), the cis-acting packaging sequences appear to be conserved among the subgroups of human adenoviruses (Schmid and Hearing, 1997). However, the primary sequence of the cis-acting packaging motif(s) of CAV-2 (nonhuman adenovirus) appears to be different, suggesting that viral elements involved in the DNA packaging might have adapted to interact with species-specific cellular factors (Soudais et al., 2001). Here, we describe the construction and characterization of packaging mutants, and the sequence motifs that appear to direct PAV-3 packaging.

Although cis-acting packaging domain of adenoviruses appears to be located near the left end of the genome, it can also be functional even when present in the last 600 bp of the right end of adenovirus genome (Hammarskjold and Winberg, 1980; Hearing and Shenk, 1983; Hearing et al., 1987). Interestingly, analysis of the right end of PAV-3 genome identified two motifs containing first element (5’-TTTG-3’) of consensus sequence of cis-acting packaging motif of HAV-5 (Schmid and Hearing, 1997). Similar motifs have been shown to be part of the cis-acting packaging domain of CAV-2 (Soudais et al., 2001). However, mutant PAV-3s containing deletion of one or both motifs (5’-TTTG-3’) grew as well as wild-type virus, suggesting that these motifs are not involved in the packaging of PAV-3 genome. In contrast, analysis of PAV-3 mutants containing deletions in the left end of PAV-3 identified functional cis-acting packaging domain to 319 bp (nt 212 to 531), which showed no sequence homology to bipartite packaging motif of HAV-5 (Schmid and Hearing, 1997). Additionally, aside from AT/GC-rich character, none of the potential packaging motifs showed any primary sequence homology. These results confirm earlier observations (Soudais et al., 2001) and further suggest that primary sequence requirements for packaging motif(s) may be different for adenoviruses of different species.

Of the five known PAV serotypes (Derbyshire et al., 1975; Hirahara et al., 1990), DNA sequences of only PAV-3 (Reddy et al., 1998a, b) and PAV-5 (Nagy et al., 2001) are known. Analysis of the left end of PAV-5 genome does not contain putative cis-acting packaging motifs identified in HAV-5 (Schmid and Hearing, 1997) and CAV-2 (Soudais et al., 2001). In contrast, we could identify AT/GC-rich motifs between left ITR and ATG of E1A of PAV-5 genome. Interestingly, the number and organization of these AT/GC-rich motifs appear similar to those identified in PAV-3 (Table 2), suggesting that other porcine adenoviruses may have identical cis-acting packaging motifs. Although more data are required to draw a conclusion, it appears that adenoviruses infecting the same host may have similar packaging motifs, which will allow them to interact with viral and host-specific cellular factors.

PAV-3 packaging domain contains six AT/GC-rich elements, one of which contains consensus sequence (5’-TTTG-3’) of cis-acting packaging domain of CAV-2 (Sou-
Interestingly, another packaging motif overlaps the TATA box (nt 449–454) of the E1A promoter. Although the AT/GC-rich motifs appear to be functionally redundant and have additive effect on the packaging efficiency, these motifs (individual or combination) do not appear to be functionally equivalent in VIDO R1 cells. These results are consistent with the suggestions that different packaging factors may interact with different packaging motifs depending upon the type of cells infected (Soudais et al., 2001).

---

### Fig. 5. Analysis of viral mutants carrying progressive deletions with a common start site at nt 151.

<table>
<thead>
<tr>
<th>Mutant</th>
<th>YIELD</th>
<th>COINF.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pav3-151/254</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Pav3-151/313</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>Pav3-151/383</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>Pav3-151/433</td>
<td>20</td>
<td>5</td>
</tr>
<tr>
<td>Pav3-151/449</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>Pav3-151/474</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>Pav3-151/497</td>
<td>10</td>
<td>7</td>
</tr>
</tbody>
</table>

---

### Fig. 6. Analysis of viral mutants carrying progressive deletions with a common start site at nt 531.

<table>
<thead>
<tr>
<th>Mutant</th>
<th>YIELD</th>
<th>COINF.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pav3-252/531</td>
<td>NV</td>
<td></td>
</tr>
<tr>
<td>Pav3-312/531</td>
<td>12</td>
<td>9</td>
</tr>
<tr>
<td>Pav3-382/531</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>Pav3-432/531</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Pav3-447/531</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Pav3-461/531</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>

---

**Legend to Fig. 5:**
- (A) The schematic, mutant names, endpoints of the deletion, and in vivo packaging analysis are as described in the legend to Fig. 4A.
- (B) Southern hybridization analysis of total and virion DNA isolated from VIDO R1 cells coinfected with wild-type and individual mutant viruses. Southern hybridization analysis of total DNA and virion DNA was performed as described in the legend to Fig. 4B.

---

**Legend to Fig. 6:**
- (A) The schematic, mutant names, endpoints of the deletion, and in vivo packaging analysis are as described in the legend to Fig. 4A.
- (B) Southern hybridization analysis of total and virion DNA isolated from VIDO R1 cells coinfected with wild-type and individual mutant viruses. Southern hybridization analysis of total DNA and virion DNA was performed as described in the legend to Fig. 4B.

---

**Legend to A:**
- YIELD and COINF. columns represent the yield and coinfection efficiency of the mutants.

---

**Legend to B:**
- **Total** and **Virion** columns represent the results of Southern hybridization analysis of total and virion DNA, respectively.
- WT and MU represent wild-type and mutant virus, respectively.
Several mutant viruses exhibited an unexpected decrease in the virus yield in a single infection. As these mutant viruses showed comparable packaging capacity in coinfec-
tion experiments with wild-type PAV-3, the defect appeared to be in the absence of a trans-acting factor(s). Our results suggest that a cis-acting element required for this effect is located between nt 252 and 312. In HAV-5, the cis-acting packaging domain overlaps two distinct transcriptional enhancer elements. Element I specifically stimulates E1A transcription (Hearing and Shenk, 1986) upon binding of a cellular factor EF1A (Bruder and Hearing, 1989). Element I mutants can be efficiently complemented in single infection by propagation of virus in E1-expressing cells (e.g., 293 cells) (Graham et al., 1977). In contrast, element II enhances transcription from all early transcription units. Element II mutants can be efficiently complemented in trans by providing all of the gene products in a mixed infection with wild-type virus (Hearing and Shenk, 1986). Although the nature of the defect in these PAV-3 mutants is not known, it is possible that this region may regulate viral gene expression similar to the enhancer element II of HAV-5 E1A transcription unit (Hearing and Shenk, 1983, 1986).

Some mutant HAV-5 (Grable and Hearing, 1990) or CAV-2 (Soudais et al., 2001) viruses showed dramatic reduction in the virus yield in single infections or coinfec-
tions. In contrast, the effects of most of the deletion muta-
tions on mutant PAV-3 yield ranged from 2- to 20-fold except on two nonviable mutant PAV-3s. It is possible that a functionally intact packaging motif(s) critical for DNA packaging is present in these mutants. Alternatively, the effect of spatial changes between individual packaging mo-
tifs may not affect virus yield in PAV-3 as severely as observed in HAV-5 (Schmid and Hearing, 1997).

Knowledge of requirements of DNA packaging of PAV-3 has important implications for the development of improved gutless adenovirus gene transfer vectors. Gutless or helper-dependent adenovirus vectors have demonstrated great promise in reducing the host immune response against virus encoded proteins and extending the expression of therapeutic gene (Balague et al., 2000; Chen et al., 1997; Cregan et al., 2000; Kim et al., 2001; Maione et al., 2000; Morral et al., 1998,1999; Morsy et al., 1998; Oka et al., 2001; Schiedner et al., 1998; Thomas et al., 2000; Zhou et al., 2001). Although a number of approaches have been developed to make gutless adenovirus vectors (Ng et al., 2001; Parks et al., 1996; Sandig et al., 2000; Umana et al., 2001; Zhou et al., 2001), all of them still leave a significant level of helper virus contamination. Based on the availability of cis-acting packaging domain of PAV-3, and the growth properties of PAV-3 in human cells, a system can be developed where vector DNA is specifically packaged. In this system, helper vector (containing PAV-3 packaging domain) and recombinant vector (containing PAV-3 and

### Table 2

<table>
<thead>
<tr>
<th>Virus</th>
<th>Packaging motif</th>
<th>Sequence&lt;sup&gt;a&lt;/sup&gt;</th>
<th>A/T nucleotide&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PAV-3</td>
<td>I</td>
<td>GCGG AAATT CCCG</td>
<td>233–237</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td>CCGG ATTTT GTGC</td>
<td>264–268</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>CCGG TATT CCCCC</td>
<td>334–337</td>
</tr>
<tr>
<td></td>
<td>IV</td>
<td>GGTT TATTTTT CCCCC</td>
<td>431–438</td>
</tr>
<tr>
<td></td>
<td>V</td>
<td>AGTG TATATA GTCC</td>
<td>449–454</td>
</tr>
<tr>
<td></td>
<td>VI</td>
<td>AGAG TTTT CCTT</td>
<td>505–508</td>
</tr>
<tr>
<td>PAV-5</td>
<td>I</td>
<td>CTGG TATTTT CCAC</td>
<td>187–192</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td>TGGT ATATT GGAC</td>
<td>207–211</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>GACC TTTA CCTG</td>
<td>217–220</td>
</tr>
<tr>
<td></td>
<td>IV</td>
<td>AATCT AATTCC CCAC</td>
<td>271–277</td>
</tr>
<tr>
<td></td>
<td>V</td>
<td>GTGC ATTTTT CCAC</td>
<td>321–326</td>
</tr>
<tr>
<td></td>
<td>VI</td>
<td>TCCC TATTTATT CTGC</td>
<td>349–356</td>
</tr>
</tbody>
</table>

<sup>a</sup> AT-rich sequences are indicated in boldface type.

<sup>b</sup> Numbers indicate the nucleotide position relative to the left terminus of PAV-3 (Reddy et al., 1998b) or PAV-5 (Nagy et al., 2001) genomes.

Fig. 7. Analysis of viral mutants carrying progressive deletions with a common start site at nt 449. The schematic, mutant names, endpoints of the deletion, and in vivo packaging analysis are as described in the legend to Fig. 4A. (B) Southern hybridization analysis of total and virion DNA isolated from VIDO R1 cells coinfected with wild-type and individual mutant viruses. Southern hybridization analysis of total DNA and virion DNA was performed as described in the legend to Fig. 4B. The mutant viruses tested were Pav3-212/449 (lane 1), Pav3-252/449 (lane 2), Pav3-312/449 (lane 3), and Pav3-382/449 (lane 4).
HAV-5 packaging domains) will be transfected into porcine cells infected with PAV-3, leading to the production of three types of viral particles. This mixture can be used to infect human cells which will only package genomes containing HAV-5 packaging domain, thus helping to eliminate or substantially reduce the helper virus contamination.

Materials and methods

Cells and viruses

VIDO R1 cells (HAV-5 E1-expressing fetal porcine retina cells) (Reddy et al., 1999b) were grown and maintained in Eagle’s minimum essential medium (MEM) supplemented with 10% fetal bovine serum (FBS). The wild-type (6618 strain) (Clarke et al., 1967) and mutant PAV-3s were propagated and titrated in VIDO R1 cells.

Construction of recombinant plasmids

A 6.814-kb Eco47-3 fragment [containing vector backbone plus the left (nt 1–2192) and right (nt 31499–34094) termini of the PAV-3 genome] isolated from pFPAV200 (Reddy et al., 1999a) was religated, creating plasmid pPAV3.Eco47-3 (Fig. 2A). Nucleotide numbers of the PAV-3 genome referred to in this article are given according to GenBank Accession No. AF083132. This plasmid DNA containing both the ends of PAV-3 genome was used as template in PCR amplifications using specific primers (Table 1) to create specific deletion between left ITR and ATG of E1A gene (Reddy et al., 1998b). The following conditions were used for PCR in a total volume of 50 μl: 0.5 μg of template DNA, 1× PCR buffer [10 mM KCl, 10 mM (NH₄)₂SO₄, 20 mM Tris–Cl (pH 8.75), 2 mM MgSO₄, 0.1% Triton X-100, 0.1 mg/ml BSA; Stratagene], 0.4 mM dNTPs, 10 pmol of each primer, 2.0 U of cloned DNA polymerase (Stratagene). The cycling conditions were 94°C for 2 min to denature the DNA, followed by 30 cycles consisting of 94°C for 40 s, 50°C for 40 s, 72°C for 40 s, and finally, extention at 72°C for 2 min. The products of PCR were separated on a 2% agarose gel and visualized by ethidium bromide (EtBr) staining.

To construct recombinant transfer plasmids containing the desired deletions between left-end ITR and ATG codon of E1A gene of PAV-3 (Figs. 4A, 5A, 6A, and 7A). To construct the recombinant plasmids containing the deletions between right-end ITR and E4 gene of PAV-3, first the DNA fragments amplified using primer pairs PR1-PR3 and PR1-PR5 were digested with HpaI and MfeI. Second, the DNA fragments amplified using primer pairs PR2-PR4 and PR2-PR6 were digested with MfeI and PacI. The appropriate HpaI-MfeI and MfeI-Paci DNA fragments were ligated to HpaI-Paci-digested pPAV3.Eco47-3 in a three-way ligation, thus creating the recombinant transfer plasmids containing the desired deletions between E4 and right-end ITR (Fig. 4A).

The plasmids containing the full-length genome of PAV-3 with deletions in the putative packaging domain were generated by homologous recombination in E. coli BJ5183 (Chartier et al., 1996) between Eco47-3-linearized individual recombinant transfer plasmid and the genomic DNA from wild-type PAV-3 (Fig. 2B). These plasmids were characterized by restriction endonuclease analysis. The endpoints of deletion plasmids containing the desired deletions between E4 and the right ITR (Fig. 4A) were determined by nucleotide sequence analysis.

Isolation of PAV-3 mutants

VIDO R1 cell monolayers were seeded in a 35-mm diameter dish and were transfected with 5 μg of PacI-digested individual full-length plasmid DNA using the Lipofectin methods according to the instructions of manufacturer (Invitrogen). After 10 to 15 days of incubation at 37°C, the transfected cells were collected and freeze thawed three times. The lysates were used to infect the freshly prepared VIDO R1 cells until cytopathic effect appeared. Finally, the recombinant viruses were characterized by PCR and restriction analysis and then expanded and titrated on VIDO R1 cells.

Determination of virus yields and packaging efficiency

All viral infections were performed at an multiplicity of infection (m.o.i.) of 5 plaque-forming units (PFU) per cell at 37°C for 1 h. The cells were washed and fresh medium was added. For the determination of viral yield in single-virus infections, infected VIDO R1 cells were harvested 48 h after infection and then lysed by three cycles of freezing and thawing. The infectious virus yields in cleared lysates were determined by plaque assay on VIDO R1 cells. The data presented for virus yields from single infections represent the averages of three independent experiments.

Packaging efficiency of the mutant viruses was determined by coinfection of VIDO R1 cells with both the mutant and the wild-type PAV-3, according to the method described earlier (Grable and Hearing, 1990, 1992), with little modification. VIDO R1 cells were infected with 5 PFU
of each of the viruses per cell as described above. Forty-eight hours postinfection, one-half of the cells were used to isolate high-molecular-weight DNA, and the other half of the cells were used to prepare viral DNA from virions. For the isolation of infected cell high-molecular-weight DNA, the cells were lysed by the addition of Nonidet P-40 to 0.4%, and then digested with proteinase K at 50°C for at least 2 h. The high-molecular-weight DNA was isolated as described previously (Sambrook et al., 1989). For the isolation of viral DNA from virions, infected cells were pelleted and suspended in lysis buffer [20 mM Tris–Cl (pH 8.0), 0.2% deoxycholate, 10% ethanol]. After incubation for 60 min at room temperature, the lysate was cleared at 10,000 g for 30 min. The supernatant was adjusted to 2 mM CaCl₂ and 2 mM MgCl₂, and was digested with 40 μg of RNase A per milliliter and 10 μg of DNase I per milliliter at 37°C for 30 min. The reaction was stopped by the addition of EDTA and EGTA to a final concentration of 50 mM each. Virus particles were lysed by the addition of Sarkosyl to 0.5%, and the samples were digested with 1 mg of proteinase K per milliliter at 50°C for 1 to 2 h. After phenol and chloroform extraction, the viral DNA was precipitated with ethanol. The DNAs isolated from cells or virions were digested with MfeI and KpnI and then analyzed by Southern hybridization.

Southern hybridization

The MfeI- and KpnI-digested DNAs were separated on 1.5% agarose gel and then transferred to Gene Screen Plus hybridization transfer membrane (Perkin–Elmer Life Science) by high salt capillary transfer method according to the instructions of the manufacturer. The 314-bp DNA fragment corresponding to n4 531–844 was amplified by PCR with primers P2 and P20, labeled with [³²P]-dCTP by the random primer method using Random Primers DNA labeling system (Invitrogen), and used as a probe in Southern hybridization analysis. The blots were prehybridized in ULTRAhyb ultrasmooth hybridization buffer (Ambion RNA) at 42°C for 30 min, and then [³²P]-labeled probes were added. Hybridization was performed at 42°C overnight. After extensively washing with 0.1× SSC and 0.1% SDS, the blots were exposed to X-ray film (Kodak) without an intensifying screen. The bands in autoradiograms were scanned and their relative intensities were determined and analyzed by Computing Densitometer using phosphoimager program. The data presented for packaging efficiency based on coinfection experiments represent the averages of three independent experiments.

Acknowledgments

We thank Jill Van Kessel, Wayne Connors, Caron Pyne, and other members of the laboratory for help and suggestions. This work was supported by a Strategic Project grant from Natural Sciences and Engineering Research Council of Canada to S.K.T.

References


Hearing, P., Shenk, T., 1986. The adenovirus type 5 E1A enhancer contains two functionally distinct domains: one is specific for E1A and the other modulates all early units in cis. Cell. 45, 229–236.


